论文部分内容阅读
目的探讨尤瑞克林联合依达拉奉治疗急性脑梗死的疗效及临床分析。方法 2010年8月至2012年8月期间,我院诊治的90例急性脑梗死患者,两组均给予常规对症治疗,随机将其分为对照组(单纯依达拉奉治疗)和观察组(尤瑞克林联合依达拉奉治疗),每组各45例,治疗2周后,对两组临床疗效和NIHSS评分,进行观察和比较。结果与对照组相比,观察组总有效率明显升高,P<0.05,差异有统计学意义;与治疗前相比,治疗后两组NIHSS评分明显降低,治疗后,与对照组相比,观察组NIHSS评分明显降低,P<0.05,差异有统计学意义。结论对于急性脑梗死患者,尤瑞克林联合依达拉奉治疗疗效显著,明显改善患者预后质量,值得临床推广。
Objective To investigate the curative effect and clinical analysis of uracil combined edaravone in the treatment of acute cerebral infarction. Methods From August 2010 to August 2012, 90 patients with acute cerebral infarction treated in our hospital were given conventional symptomatic treatment and were randomly divided into control group (edaravone alone) and observation group ( Erika Lin combined edaravone treatment), each group of 45 cases, after 2 weeks of treatment, the clinical efficacy and NIHSS scores were observed and compared. Results Compared with the control group, the total effective rate of the observation group was significantly increased, P <0.05, the difference was statistically significant; compared with before treatment, the NIHSS score decreased significantly after treatment, after treatment, compared with the control group, NIHSS score in observation group was significantly lower, P <0.05, the difference was statistically significant. Conclusion For patients with acute cerebral infarction, the combination of ureclin and edaravone has significant curative effect, which obviously improves the prognosis quality of patients and deserves clinical promotion.